{"id":"W4361026527","doi":"10.1016/s1470-2045(23)00063-3","title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; University of Alberta; Ottawa Hospital; Queen's University; Kingston Health Sciences Centre; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Docetaxel; Enzalutamide; Clinical endpoint; Prostate cancer; Internal medicine; Antiandrogen; Population; Flutamide; Oncology; Interim analysis; Bicalutamide; Testosterone (patch); Urology; Randomized controlled trial; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001515198,0.002194305,0.003081658,0.0004471272,0.0003947905,0.001122257,0.001061149,0.001706351,0.009970038],"category_scores_gemma":[0.001592092,0.0006533123,0.002944414,0.0005429157,0.001379259,0.00131128,0.0004485231,0.003865328,0.001156311],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009664821,"about_ca_system_score_gemma":0.00114596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001990858,"about_ca_topic_score_gemma":0.004930199,"domain_scores_codex":[0.9994948,0.0002702676,0.0000239189,0.00009003549,0.0000377044,0.00008325897],"domain_scores_gemma":[0.999252,0.0002530026,0.0001442758,0.00005343083,0.00003443876,0.0002628754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9823576,0.002241645,0.0002291052,0.0006160503,0.001051759,0.0000265992,0.00003660977,0.0003951933,0.000985397,0.0001286842,0.0009120363,0.01101925],"study_design_scores_gemma":[0.9680862,0.02962668,0.0007408383,0.00003530495,0.0004107091,0.00003181322,0.00001791083,0.0002720974,0.0001230561,0.0001713886,0.000469595,0.00001437809],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9743251,0.01307457,0.00103329,0.001491873,0.001206941,0.002326473,0.002004102,0.0003124218,0.004225257],"genre_scores_gemma":[0.9798641,0.005753921,0.002017633,0.001535268,0.0005690985,0.002245839,0.001801196,0.00005956629,0.006153404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009970038,"threshold_uncertainty_score":0.03335309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.200267697456237,"score_gpt":0.4825725563967049,"score_spread":0.2823048589404679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}